COX-2 inhibitors: increased risk of CV events?

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2001年 / 867卷 / 1期

关键词：

Celecoxib; Naproxen; Rofecoxib; Nabumetone; Adverse Event Reporting System;

D O I：

10.2165/00128415-200108670-00001

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[41] Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology
Clark, DWJ
Layton, D
Shakir, SAW
DRUG SAFETY, 2004, 27 (07) : 427 - 456
[42] Nimesulide and COX-2 inhibitors
Bakhle, YS
LANCET, 1999, 354 (9180): : 772 - 772
[43] No redemption for COX-2 inhibitors
Dorey, Emma
CHEMISTRY & INDUSTRY, 2006, (23) : 7 - 7
[44] Selective inhibitors of COX-2
不详
EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (01) : 79 - 80
[45] Selective COX-2 inhibitors
Parnham, MJ
DRUG NEWS & PERSPECTIVES, 1997, 10 (03) : 182 - 187
[46] COX-2 inhibitors in oncology
Haller, DG
SEMINARS IN ONCOLOGY, 2003, 30 (04) : 2 - 8
[47] Pharmacology of COX-2 inhibitors
Isakson, PC
COX-2: A NEW TARGET FOR CANCER PREVENTION AND TREATMENT, 2003, 37 : 25 - 51
[48] Selective COX-2 inhibitors
Pasero, C
McCaffery, M
AMERICAN JOURNAL OF NURSING, 2001, 101 (04) : 55 - 56
[49] COX-2 inhibitors: A review
Houston, AM
Teach, SJ
PEDIATRIC EMERGENCY CARE, 2004, 20 (06) : 396 - 399
[50] COX-2 inhibitors and the kidney
Appel, GB
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (06) : S37 - S40

← 1 2 3 4 5 →